Engineering the future of genetic medicine
Joined April 2017
- Tweets 687
- Following 3
- Followers 1,592
- Likes 52
312 Photos and videos
Pinned Tweet
Jan 20
We're pleased to announce:
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
2
3
16
1,863
Jun 12
Our go-to recipe for a team brunch? Good food and even better company. At Scribe, we have it down to a science. 🧑🍳
1
3
109
Jun 10
In Precision Medicine Online, read about our first clinical trial for STX-1150, our novel, in vivo therapy designed to epigenetically silence PCSK9 and deliver sustained LDL-C reduction after a single dose – without permanently altering DNA.
📖 precisionmedicineonline.com/…
5
6
435
May 28
At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose.
Study highlights below ⬇️
1
5
8
451
May 28
Read the full report in our press release: businesswire.com/news/home/2…
@EASCongress #CRISPR #EpigeneticEditing #CVD
147
May 25
#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic.
Thanks to @EASCongress for featuring it!
5
11
369
May 22
In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️
1
4
6
339
May 22
📰 @theheraldsun article: heraldsun.com.au/health/unbe…
🎤 If you're at #EASCongress2026 on Monday, May 25, check out the late-breaking oral presentation by Scribe co-founder and CEO @BenjaminLOakes, highlighting our preclinical data for STX-1150: businesswire.com/news/home/2…
@EASCongress
1
1
178
May 21
Announcing our first clinical trial.
Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD).
Details🧵
1
4
11
4,649
May 21
STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients.
Link to our full announcement below ❤️🩹
1
3
554
May 21
More details on our clinical trial and commentary from Scribe CEO @BenjaminLOakes and Principal Investigator Stephen Nicholls (@MonashVHI, Victorian Heart Hospital, @MonashUni, @MonashHealth):
businesswire.com/news/home/2…
#CVD #HeartHealth #CRISPR #EpigeneticEditing
1
141
May 18
At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing.
Highlights of our three oral presentations below and in thread 🧵
businesswire.com/news/home/2…
1
3
5
260
May 18
🧬 Allosteric ELXR epigenetic silencers designed to improve specificity while still achieving potent and durable target repression
⚒️ XE gene editing engineering advancements, supported by mechanistic insights into guide potency and AI-enabled predictive modeling through DeepXE
1
1
97
May 18
♥️ How our CRISPR by Design engineering approach integrates engineering of both the XE foundation to ELXR silencing machinery to enable Scribe’s lead cardiometabolic asset for LDL-C lowering
@ASGCTherapy #CRISPR #EpigeneticEditing #GeneEditing
1
2
92
May 14
Two #ASGCT26 oral presentations tomorrow!
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
1
2
242
May 11
We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation @BStaahl. Details below & more to come at @ASGCTherapy later this week!
🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability
🕒 May 11 at 3:07 pm ET
1
4
7
204
Apr 30
🔬At #ASGCT2026, we'll be delivering 2 oral presentations and one workshop presentation featuring latest advances to our ELXR epigenetic silencing and X-Editor genome editing technologies, including DeepXE, our AI-enabled CRISPR design platform for predicting editing efficiency.
1
1
1
113
Apr 30
📊At #EASCongress2026, our late-breaker will report preclinical data for STX-1150, our PCSK9-targeting epigenetic silencing therapy for LDL-C lowering.
🔗 For more details, read our press release: businesswire.com/news/home/2…
1
3
1,347